Syndax Pharmaceuticals (SNDX) Receivables - Other (2015 - 2026)

Syndax Pharmaceuticals' Receivables - Other history runs 12 years deep, the most recent figure standing at $24.7 million for Q1 2026.

• On a quarterly basis, Receivables - Other rose 139.81% year-over-year to $24.7 million in Q1 2026; TTM through Mar 2026 was $24.7 million, a 139.81% increase from a year earlier, with the FY2025 full-year figure at $28.1 million, up 673.04% from the prior year.
• Receivables - Other grew to $24.7 million in Q1 2026 per SNDX's latest filing, from $6.4 million in the prior quarter.
• Across five years, Receivables - Other topped out at $24.7 million in Q1 2026 and bottomed at $158000.0 in Q1 2022.
• The 5-year median for Receivables - Other is $3.5 million (2024), against an average of $6.2 million.
• Across the five-year window, Receivables - Other jumped 2393.96% in 2022 and slumped 82.64% in 2023, its largest moves.
• Year by year, Receivables - Other stood at $3.5 million in 2022, then sank by 64.68% to $1.2 million in 2023, then jumped by 196.25% to $3.6 million in 2024, then surged by 76.18% to $6.4 million in 2025, then surged by 285.7% to $24.7 million in 2026.
• Per Business Quant, the three latest SNDX Receivables - Other figures stand at $24.7 million (Q1 2026), $6.4 million (Q4 2025), and $20.9 million (Q3 2025).